Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 384-398

  Morrison, Ludivine Coudière ^a   McClelland, Robyn ^a   Aiken, Christopher ^a   Bridges, Melissa ^a   Liang, Lisa ^a   Wang, Xin ^b   Di Curzio, Domenico ^a   Del Bigio, Marc R ^a   Taylor, Michael D ^b   Werbowetski Ogilvie, Tamra E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ADAPTOR PROTEIN; BETA TUBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CD133 ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CD30 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; DIPEPTIDYL PEPTIDASE IV; ELASTASE; EPHRIN RECEPTOR B1; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B3; EPHRIN RECEPTOR B6; FATTY ACID BINDING PROTEIN; FLUOROURACIL; HERMES ANTIGEN; INTERLEUKIN 31; NUCLEAR FACTOR I; P21 ACTIVATED KINASE 3; PROTEIN PATCHED 2; SERINE PROTEINASE; SMAD PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SOX1; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HETEROGENEITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL RENEWAL; CELL STRUCTURE; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FETUS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NERVE FIBER; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84875649052     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13148     Document Type: Article

References (51)

1. Louis D, Ohgaki H, Wiestler OD, and Cavenee WK (2007). WHO Classification of Tumours of the Central Nervous System (4th ed). International Agency for Research on Cancer (IARC), Lyon, France.
2. Mehta M, Chang S, Newton H, Guha A, and Vogelbaum M (2011). Principles and Practice of Neuro-oncology: A Multidisciplinary Approach. (1st ed). Demos Medical Publishing (Oct 21 2010), New York, NY.
3. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, et al. (2012). Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533.
4. Rosen JM and Jordan CT (2009). The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673.
5. Visvader JE (2011). Cells of origin in cancer. Nature 469, 314-322.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, and Dirks PB (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, CusimanoMD, and Dirks PB (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
8. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, et al. (2008). CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122, 761-768.
9. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al. (2008). Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88, 808-815.
10. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al. (2008). CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 118, 2111-2120.
11. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, et al. (2008). Identification of A2B5+ CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 62, 505-514; discussion 514-505.
12. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, et al. (2010). A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17, 362-375.
13. Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, and Wechsler-Reya RJ (2009). Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15, 135-147.
14. Ward RJ, Lee L, Graham K, Satkunendran T, Yoshikawa K, Ling E, Harper L, Austin R, Nieuwenhuis E, Clarke ID, et al. (2009). Multipotent CD15+ cancer stem cells in patched-1-deficientmouse medulloblastoma. Cancer Res 69, 4682-4690.
15. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, and Lander ES (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644.
16. Giese A, Bjerkvig R, BerensME, andWestphalM(2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636.
17. Greig NH (1987). Optimizing drug delivery to brain tumors. Cancer Treat Rev 14, 1-28.
18. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
19. Blazek ER, Foutch JL, and Maki G (2007). Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67, 1-5.
20. Eyler CE and Rich JN (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26, 2839-2845.
21. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, and Yu JS (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5, 67.
22. Singh A and Settleman J (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
24. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al. (2010). A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603-615.
25. Weber K, Paulus W, and Senner V (2010). The side population of gliomas exhibits decreased cell migration. J Neuropathol Exp Neurol 69, 623-631.
26. Molina JR, Hayashi Y, Stephens C, andGeorgescuMM(2010). Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 12, 453-463.
27. Werbowetski-Ogilvie TE, Morrison LC, Fiebig-Comyn A, and Bhatia M (2012). In vivo generation of neural tumors from neoplastic pluripotent stem cells models early human pediatric brain tumor formation. Stem Cells 30, 392-404.
28. Del Duca D, Werbowetski T, and Del Maestro RF (2004). Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 67, 295-303.
29. Werbowetski-Ogilvie TE, Seyed Sadr M, Jabado N, Angers-Loustau A, Agar NY, Wu J, Bjerkvig R, Antel JP, Faury D, Rao Y, et al. (2006). Inhibition of medulloblastoma cell invasion by Slit. Oncogene 25, 5103-5112.
30. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, et al. (2011). Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29, 1408-1414.
31. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, ParsonsDW, Rutkowski S, Gajjar A, et al. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123, 465-472.
32. Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, and Alvarez-Buylla A (2002). EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 36, 1021-1034.
33. Calaora V, Chazal G, Nielsen PJ, Rougon G, and Moreau H (1996). mCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Neuroscience 73, 581-594.
34. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, and Weissman IL (2000). Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97, 14720-14725.
35. Pruszak J, Ludwig W, Blak A, Alavian K, and Isacson O (2009). CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 27, 2928-2940.
36. Chen Y, Zeng J, Cen L, Wang X, Yao G, Wang W, Qi W, and Kong K (2009). Multiple roles of the p75 neurotrophin receptor in the nervous system. J Int Med Res 37, 281-288.
37. Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, et al. (2007). The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol 5, e212.
38. Wang L, Rahn JJ, Lun X, Sun B, Kelly JJ, Weiss S, Robbins SM, Forsyth PA, and Senger DL (2008). Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol 6, e289.
39. Barnes M, Eberhart CG, Collins R, and Tihan T (2009). Expression of p75NTR in fetal brain and medulloblastomas: evidence of a precursor cell marker and its persistence in neoplasia. J Neurooncol 92, 193-201.
40. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Schuller U, Machold R, Fishell G, Rowitch DH, et al. (2008). Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14, 135-145.
41. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al. (2008). Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 14, 123-134.
42. Wang X, Cui M, Wang L, Chen X, and Xin P (2010). Inhibition of neurotrophin receptor p75 intramembran proteolysis by gamma-secretase inhibitor reduces medulloblastoma spinal metastasis. Biochem Biophys Res Commun 403, 264-269.
43. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, and Frisen J (2006). p53 suppresses the self-renewal of adult neural stem cells. Development 133, 363-369.
44. Pasquale EB (2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52.
45. Lim YS, McLaughlin T, Sung TC, Santiago A, Lee KF, and O'Leary DD (2008). p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59, 746-758.
46. Naska S, Lin DC, Miller FD, and Kaplan DR (2010). p75NTR is an obligate signaling receptor required for cues that cause sympathetic neuron growth cone collapse. Mol Cell Neurosci 45, 108-120.
47. Nakada M, Niska JA, Miyamori H, McDonough WS, Wu J, Sato H, and Berens ME (2004). The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 64, 3179-3185.
48. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, Sloan A, Coons SW, and Berens ME (2005). Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7, 7-16.
49. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, et al. (2009). EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20.
50. Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, et al. (2012). EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol 14, 1125-1135.
51. Wang SD, Rath P, Lal B, Richard JP, Li Y, Goodwin CR, Laterra J, and Xia S (2012). EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene 31, 5132-5143.